Researchers analyzed requests for assistance from patients with cancer enrolled in a novel digital support registry. Medscape Medical News
Tag: Hematology-Oncology
FDA Approves New ADC for Lung Cancer Treatment
Dr Mark Kris discusses datopotamab deruxtecan as a potent option post-osimertinib but warns of toxicity patterns unfamiliar to many lung oncologists. Medscape Oncology
Efficacy and Toxicity Seen With MIRV in Ovarian Cancer
New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in patients with platinum-sensitive ovarian cancer. Medscape Medical News
Kraft: The “Medaverse” Means New Roles for Clinicians
Working with a blend of AI tools and avatars, Daniel Kraft sees dramatic changes in how future clinicians will interact with patients. Medscape
‘Alarming Disparities’ in Cancer Trends and Shift to Women, Younger Adults
Annual cancer statistics report identifies persistent racial and ethnic disparities and increases in certain cancers in women and younger adults. Medscape Medical News
Olaparib Protects Patients From High-Risk Cancer Recurrences
The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first patient in the phase 3 OlympiA trial was enrolled. Medscape Medical News
Eye Toxicities Are a Growing Concern With Certain ADCs
Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop treatment, yet many oncologists are unaware of the risks, experts warned. Medscape Medical News
Trastuzumab Duocarmazine Tried in HER2+ Breast Cancer
Patients with unresectable locally advanced or metastatic HER2+ breast cancer were randomly assigned to receive trastuzumab duocarmazine or a physician’s choice. Medscape Medical News
Three vs Six Cycles of Chemo for Retinoblastoma
Participants were randomly assigned to receive either three or six cycles of CEV chemotherapy after enucleation. Medscape Medical News
Hereditary Amyloidosis: 5 Things to Know
The heterogeneity of hereditary amyloidosis can delay diagnosis and seriously affect prognosis and patient quality of life; these five things are need-to-know. Medscape Oncology
Europe Approves Neutropenia and Schizophrenia Treatments
Recommendations were also endorsed to institute measures to reduce risks from cold and flu medicines containing pseudoephedrine. Medscape Medical News
Ocular Toxicity With New Drugs for Gynecologic Cancers
Antibody-drug conjugates are a promising new option for gynecologic cancers, but they have a variety of ocular or vision-related adverse events that need to be appropriately monitored and managed. Medscape Medical News
Novel Drug, First Tx for Rare Uveal Melanoma
A novel drug, the first in its class, is also the first treatment approved for use in uveal melanoma, a rare cancer of the eye, after it was shown to improve overall survival. FDA Approvals
Novel Drug, First Tx Approved for Rare Uveal Melanoma
A novel drug, the first in its class, is also the first treatment approved for use in uveal melanoma, a rare cancer of the eye, after it was shown to improve overall survival. FDA Approvals
Tebentafusp improves OS: A First in Metastatic Uveal Melanoma
First-line tebentafusp significantly improved overall survival (OS) when compared with immunotherapy or chemotherapy in patients with metastatic uveal melanoma in a phase 3 trial. Medscape Medical News
Companies Are Profiting From Health Data—Patients Should Too
The rise of medical records has created a booming trade in health data — much of it without patients’ knowledge. Medscape Oncology
Companies Are Profiting From Health Data—Patients Should Too
The rise of medical records has created a booming trade in health data — much of it without patients’ knowledge. Medscape Oncology
Are We Healthcare Heroes or Doomsayers?
A physician faces his daughter’s disregard for social distancing amid the COVID-19 pandemic. Medscape Oncology
Text #FlipYourScrip to Easily Donate Unused Drugs
Throwing away leftover medications is an environmental and financial waste. Now clinicians and individuals can pass them onto needy patients. Medscape Medical News
Stopping the Med School ‘Arms Race’
Does an impressive CV really make a better doctor? Medscape Oncology